Effect of different asthma treatments on risk of cold-related exacerbations

European Respiratory Journal

Volumn 38, Issue 3, 2011, Pages 584-593

  Reddel, H K ^a   Jenkins, C ^a   Quirce, S ^b   Sears, M R ^c   Bateman, E D ^d   O'Byrne, P M ^c   Humbert, M ^e   Buhl, R ^f   Harrison, T ^g   Brusselle, G G ^h   Thoren A ⁱ   Sjobring U ⁱ   Peterson, S ⁱ   Ostlund O ⁱ   Eriksson, G S ⁱ  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e HÔPITAL ANTOINE BÉCLÈRE   (France)

^f UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^g UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^h GHENT UNIVERSITY HOSPITAL   (Belgium)

ⁱ LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Asthma; Drug therapy; Exacerbations; Respiratory tract infections

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FORMOTEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CHILD; COMMON COLD; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HUMAN; INCIDENCE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ASTHMA; BUDESONIDE; CHILD; CHILD, PRESCHOOL; COMMON COLD; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; POISSON DISTRIBUTION; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; RISK; TIME FACTORS;

EID: 80053086068     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00186510     Document Type: Article

References (45)

1. Corne JM, Marshall C, Smith S, et al. Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. Lancet 2002; 359: 831-834. (Pubitemid 34233753)
2. Message SD, Laza-Stanca V, Mallia P, et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci USA 2008; 105: 13562-13567.
3. Jackson DJ, Johnston SL. The role of viruses in acute exacerbations of asthma. J Allergy Clin Immunol 2010; 125: 1178-1187.
4. Wark PAB, Johnston SL, Moric I, et al. Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma. Eur Respir J 2002; 19: 68-75. (Pubitemid 34105570)
5. Sin DD, Man J, Sharpe H, et al. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA 2004; 292: 367-376. (Pubitemid 38944262)
6. Gibson PG, Wong BJO, Hepperle MJE, et al. A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid. Clin Exp Allergy 1992; 22: 525-532.
7. Gauvreau GM, Evans MY. Allergen inhalation challenge: a human model of asthma exacerbation. Contrib Microbiol 2007; 14: 21-32.
8. Reddel H, Ware S, Marks G, et al. Differences between asthma exacerbations and poor asthma control. Lancet 1999; 353: 364-369. (Pubitemid 29088164)
9. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27: 483-494. (Pubitemid 43372521)
10. Edwards MR, Johnson MW, Johnston SL. Combination therapy: synergistic suppression of virus-induced chemokines in airway epithelial cells. Am J Respir Cell Mol Biol 2006; 34: 616-624.
11. Edwards MR, Haas J, Panettieri RA, et al. Corticosteroids and b2 agonists differentially regulate rhinovirus-induced interleukin-6 via distinct cis-acting elements. J Biol Chem 2007; 282: 15366-15375. (Pubitemid 47093295)
12. Skevaki CL, Christodoulou I, Spyridaki IS, et al. Budesonide and formoterol inhibit inflammatory mediator production by bronchial epithelial cells infected with rhinovirus. Clin Exp Allergy 2009; 39: 1700-1710.
13. Prazma CM, Kral KM, Gul N, et al. Controller medications and their effects on asthma exacerbations temporally associated with upper respiratory infections. Respir Med 2010; 104: 780-787.
14. Gibson PG, Powell H, Coughlan J, et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev 2003; 1: CD001117.
15. Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax 2004; 59: 94-99. (Pubitemid 38223477)
16. Quon BS, Fitzgerald JM, Lemiere C, et al. Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev 2010; 10: CD007524.
17. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. www.ginasthma.org/guidelinesgina- report-global-strategy-for-asthma. html Date last accessed: August 2010; Date last updated: 2010.
18. National Heart Lung and Blood Institute National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. 2007. www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm Date last accessed: September 2007; Date last updated: August 2007.
19. Chan-Yeung M, Chang JH, Manfreda J, et al. Changes in peak flow, symptom score, and the use of medications during acute exacerbations of asthma. Am J Respir Crit Care Med 1996; 154: 889-893.
20. Tattersfield AE, Postma DS, Barnes PJ, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med 1999; 160: 594-599. (Pubitemid 29380678)
21. Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004; 20: 1403-1418. (Pubitemid 39361344)
22. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171: 129-136. (Pubitemid 40105411)
23. Rabe KF, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006; 368: 744-753. (Pubitemid 44279053)
24. Kuna P, Peters MJ, Manjra AI, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007; 61: 725-736. (Pubitemid 46587876)
25. Bousquet J, Boulet LP, Peters MJ, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/ fluticasone. Respir Med 2007; 101: 2437-2446. (Pubitemid 350010579)
26. Bateman ED, Reddel HK, Eriksson G, et al. Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol 2010; 125: 600-608.
27. Joelson S, Joelson I-B, Wallander M-A. Geographical variation in adverse event reporting rates in clinical trials. Pharmacoepidemiol Drug Saf 1997; 3: S31-S35. (Pubitemid 27483538)
28. Walter MJ, Castro M, Kunselman SJ, et al. Predicting worsening asthma control following the common cold. Eur Respir J 2008; 32: 1548-1554.
29. Fahy JV, Kim KW, Liu J, et al. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol 1995; 95: 843-852.
30. Doull IJ, Lampe FC, Smith S, et al. Effect of inhaled corticosteroids on episodes of wheezing associated with viral infection in school age children: randomised double blind placebo controlled trial. BMJ 1997; 315: 858-862. (Pubitemid 27420448)
31. Grunberg K, Sharon RF, Sont JK, et al. Rhinovirus-induced airway inflammation in asthma: effect of treatment with inhaled corticosteroids before and during experimental infection. Am J Respir Crit Care Med 2001; 164: 1816-1822. (Pubitemid 33152313)
32. Suzuki T, Yamaya M, Sekizawa K, et al. Effects of dexamethasone on rhinovirus infection in cultured human tracheal epithelial cells. Am J Physiol Lung Cell Mol Physiol 2000; 278: L560-L571. (Pubitemid 30152514)
33. 2-adrenoceptor implicated? Am J Respir Cell Mol Biol 2010; 43: 227-233.
34. Johnston SL, Edwards MR. Mechanisms of adverse effects of β-agonists in asthma. Thorax 2009; 64: 739-741.
35. Biagioli MC, Kaul P, Singh I, et al. The role of oxidative stress in rhinovirus induced elaboration of IL-8 by respiratory epithelial cells. Free Radic Biol Med 1999; 26: 454-462. (Pubitemid 29013478)
36. Aldridge RE, Hancox RJ, Taylor DR, et al. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am J Respir Crit Care Med 2000; 161: 1459-1464. (Pubitemid 30329012)
37. Agarwal SK, Marshall GD Jr. Beta-adrenergic modulation of human type-1/type-2 cytokine balance. J Allergy Clin Immunol 2000; 105: 91-98. (Pubitemid 30059108)
38. 2-adrenoceptor agonists in airway epithelial cells is reversed by glucocorticoid action. Br J Pharmacol 2010; 160: 410-420.
39. 2-adrenoceptor agonists: pharmacology and molecular and cellular mechanisms. Clin Rev Allergy Immunol 2006; 31: 119-130.
40. Papi A, Caramori G, Adcock IM, et al. Rescue treatment in asthma. More than as-needed bronchodilation. Chest 2009; 135: 1628-1633.
41. FitzGerald JM, Becker A, Sears MR, et al. Canadian Asthma Exacerbation Study Group. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004; 59: 550-556. (Pubitemid 38901511)
42. Harrison TW, Oborne J, Newton S, et al. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004; 363: 271-275. (Pubitemid 38142409)
43. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcif Tissue Int 2008; 82: 249-257.
44. Kelly HW, Van Natta ML, Covar RA, et al. Effect of long-term corticosteroid use on bone mineral density in children: a prospective longitudinal assessment in the childhood Asthma Management Program (CAMP) study. Pediatrics 2008; 122: e53-e61.
45. Janson S, Becker G. Reasons for delay in seeking treatment for acute asthma: the patient's perspective. J Asthma 1998; 35: 427-435. (Pubitemid 28438362)